|
1
|
Carrle D and Bielack SS: Current
strategies of chemotherapy in osteosarcoma. Int Orthop. 30:445–451.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bielack SS, Kempf-Bielack B, Delling G, et
al: Prognostic factors in high-grade osteosarcoma of the
extremities or trunk: an analysis of 1,702 patients treated on
neoadjuvant cooperative osteosarcoma study group protocols. J Clin
Oncol. 20:776–790. 2002. View Article : Google Scholar
|
|
3
|
Tajima Y, Yamazaki K, Makino R, et al:
Gastric and intestinal phenotypic marker expression in early
differentiated-type tumors of the stomach: clinicopathologic
significance and genetic background. Clin Cancer Res. 12:6469–6479.
2006. View Article : Google Scholar
|
|
4
|
Barrow H, Rhodes JM and Yu LG: The role of
galectins in colorectal cancer progression. Int J Cancer. 129:1–8.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Alves PM, Godoy GP, Gomes DQ, et al:
Significance of galectins-1, -3, -4 and -7 in the progression of
squamous cell carcinoma of the tongue. Pathol Res Pract.
207:236–240. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Barrow H, Guo X, Wandall HH, et al: Serum
galectin-2, -4, and -8 are greatly increased in colon and breast
cancer patients and promote cancer cell adhesion to blood vascular
endothelium. Clin Cancer Res. 17:7035–7046. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kamper P, Ludvigsen M, Bendix K, et al:
Proteomic analysis identifies galectin-1 as a predictive biomarker
for relapsed/refractory disease in classical Hodgkin lymphoma.
Blood. 117:6638–6649. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tang CE, Tan T, Li C, et al:
Identification of Galectin-1 as a novel biomarker in nasopharyngeal
carcinoma by proteomic analysis. Oncol Rep. 24:495–500.
2010.PubMed/NCBI
|
|
9
|
Espelt MV, Croci DO, Bacigalupo ML, et al:
Novel roles of galectin-1 in hepatocellular carcinoma cell
adhesion, polarization, and in vivo tumor growth. Hepatology.
53:2097–2106. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xue X, Lu Z, Tang D, et al: Galectin-1
secreted by activated stellate cells in pancreatic ductal
adenocarcinoma stroma promotes proliferation and invasion of
pancreatic cancer cells: an in vitro study on the microenvironment
of pancreatic ductal adenocarcinoma. Pancreas. 40:832–839. 2011.
View Article : Google Scholar
|
|
11
|
Carlsson MC, Balog CI, Kilsgård O, et al:
Different fractions of human serum glycoproteins bind galectin-1 or
galectin-8, and their ratio may provide a refined biomarker for
pathophysiological conditions in cancer and inflammatory disease.
Biochim Biophys Acta. 1820:1366–1372. 2012. View Article : Google Scholar
|
|
12
|
Kuo PL, Huang MS, Cheng DE, et al: Lung
cancer-derived galectin-1 enhances tumorigenic potentiation of
tumor-associated dendritic cells by expressing heparin-binding
EGF-like growth factor. J Biol Chem. 287:9753–9764. 2012.
View Article : Google Scholar
|
|
13
|
Cedeno-Laurent F, Opperman M, Barthel SR,
Kuchroo VK and Dimitroff CJ: Galectin-1 triggers an
immunoregulatory signature in Th cells functionally defined by
IL-10 expression. J Immunol. 188:3127–3137. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gomez-Brouchet A, Mourcin F, Gourraud PA,
et al: Galectin-1 is a powerful marker to distinguish
chondroblastic osteosarcoma and conventional chondrosarcoma. Hum
Pathol. 41:1220–1230. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dhondge A, Surendran S, Seralathan MV, et
al: Cellular alterations and modulation of protein expression in
bitumen-challenged human osteoblast cells. Environ Sci Pollut Res
Int. 19:4030–4041. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu H, Chen P, Liao R, et al:
Overexpression of galectin-1 is associated with poor prognosis in
human hepatocellular carcinoma following resection. J Gastroenterol
Hepatol. 27:1312–1319. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim HJ, Jeon HK, Cho YJ, et al: High
galectin-1 expression correlates with poor prognosis and is
involved in epithelial ovarian cancer proliferation and invasion.
Eur J Cancer. 48:1914–1921. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu MH, Hong HC, Hong TM, et al: Targeting
galectin-1 in carcinoma-associated fibroblasts inhibits oral
squamous cell carcinoma metastasis by downregulating MCP-1/CCL2
expression. Clin Cancer Res. 17:1306–1316. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cedeno-Laurent F, Watanabe R, Teague JE,
et al: Galectin-1 inhibits the viability, proliferation, and Th1
cytokine production of nonmalignant T cells in patients with
leukemic cutaneous T-cell lymphoma. Blood. 119:3534–3538. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Satelli A and Rao US: Galectin-1 is
silenced by promoter hypermethylation and its re-expression induces
apoptosis in human colorectal cancer cells. Cancer Lett. 301:38–46.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ito K, Stannard K, Gabutero E, et al:
Galectin-1 as a potent target for cancer therapy: role in the tumor
microenvironment. Cancer Metastasis Rev. 31:763–778. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mathieu V, de Lassalle EM, Toelen J, et
al: Galectin-1 in melanoma biology and related neo-angiogenesis
processes. J Invest Dermatol. 132:2245–2254. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chandhanayingyong C, Kim Y, Staples JR, et
al: MAPK/ERK signaling in osteosarcomas, Ewing sarcomas and
chondrosarcomas: therapeutic implications and future directions.
Sarcoma. 2012:4048102012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mirzoeva OK, Das D, Heiser LM, et al:
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase
feedback signaling determine susceptibility of breast cancer cells
to MEK inhibition. Cancer Res. 69:565–572. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Roy SK, Srivastava RK and Shankar S:
Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of
FOXO transcription factor, leading to cell cycle arrest and
apoptosis in pancreatic cancer. J Mol Signal. 5:102010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chung LY, Tang SJ, Sun GH, et al:
Galectin-1 promotes lung cancer progression and chemoresistance by
upregulating p38 MAPK, ERK, and cyclooxygenase-2. Clin Cancer Res.
18:4037–4047. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tsimaratou K, Kletsas D, Kastrinakis NG,
et al: Evaluation of claspin as a proliferation marker in human
cancer and normal tissues. J Pathol. 211:331–339. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cawston TE and Wilson AJ: Understanding
the role of tissue degrading enzymes and their inhibitors in
development and disease. Best Pract Res Clin Rheumatol.
20:983–1002. 2006. View Article : Google Scholar : PubMed/NCBI
|
